1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Company
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35 2022-08-12 am EDT
10712.00 GBX   +1.96%
08/12Seagen loses arbitration against Daiichi Sankyo over drug technology
RE
08/12Seagen loses arbitration ruling against Daiichi Sankyo
RE
08/12European Stocks Close Higher After UK GDP, Eurozone Industrial Production Data
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:

- product sales (97.7%). Net sales break down by treatment area between oncology (35.7%), cardiovascular, renal and metabolic diseases (21.9%), respiratory and autoimmune diseases (16.5%), and other (25.9%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);

- collaboration revenue (2.3%).

Net sales are distributed geographically as follows: the United Kingdom (8.7%), Continental Europe (20.9%), Americas (37.5%) and Africa/Asia/Australia (32.9%).

Number of employees : 83 100 people.
Sales per Business
20202021Delta
Oncology8 461.0040.8%9 487.3634.9% +12.13%
Cardiovascular, Renal & Metabolism5 533.5726.7%5 831.4421.4% +5.38%
Respiratory & Immunology4 177.4720.1%4 387.3916.1% +5.03%
COVID-19--2 909.9010.7%-
Rare Disease--2 232.238.2%-
Other Medicines2 017.389.7%1 721.076.3% -14.69%
Collaboration566.932.7%636.952.3% +12.35%
GBP in Million
Sales per region
20202021Delta
United States6 983.2533.6%8 759.5232.2% +25.44%
China4 168.1120.1%4 364.1316% +4.7%
Japan2 001.799.6%2 468.559.1% +23.32%
United Kingdom1 357.666.5%2 359.488.7% +73.79%
Other Asia, Africa and Australasia1 196.245.8%1 729.806.4% +44.6%
Sweden800.093.9%1 688.356.2% +111.02%
Other Rest of Europe1 084.725.2%1 417.145.2% +30.65%
Germany730.693.5%1 080.494% +47.87%
Other Americas593.442.9%874.723.2% +47.4%
France509.222.5%665.312.4% +30.65%
Canada464.772.2%561.332.1% +20.78%
Spain310.371.5%420.271.5% +35.41%
Italy336.101.6%419.541.5% +24.83%
Australia219.911.1%397.731.5% +80.86%
GBP in Million
Managers
Name Title Age Since
Pascal Soriot Chief Executive Officer & Executive Director 62 2012
Aradhana Sarin Chief Financial Officer & Executive Director 47 2021
Menelas Pangalos EVP-Biopharmaceuticals Research & Development 54 2019
Pam Cheng Executive VP-Operations & Information Technology 50 2015
Henry Cremisi Medical Director - -
Regina Danielson SVP, Head-Research & Early Development - -
Katarina Ageborg Chief Compliance Officer & EVP-Sustainability - 2017
Jonathan Thomas Charles Slade Group Treasurer 56 -
Adrian Charles Noel Kemp Secretary 55 2009
Ruud Dobber, Dr. Executive VP-Biopharmaceuticals Business - 2019
Members of the board
Name Title Age Since
Leif Johansson Non-Executive Chairman 69 2012
Marcus Wallenberg Independent Non-Executive Director 65 1999
Philip Arthur John Broadley Senior Independent Non-Executive Director 60 2021
Nazneen Rahman, Dr. Independent Non-Executive Director - 2017
Sherilyn McCoy Independent Non-Executive Director 62 2017
Deborah DiSanzo Independent Non-Executive Director 61 2017
Tony Mok, Dr. Independent Non-Executive Director 60 2019
Michel Demaré Chairman-Designate 65 2022
Pascal Soriot Chief Executive Officer & Executive Director 62 2012
Euan A. Ashley, Dr. Non-Executive Director - 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,549,489,389 1,493,140,483 96.4% 0 0.0% 96.4%
Shareholders
NameEquities%
BlackRock Investment Management (UK) Ltd. 87,816,365 5.67%
Wellington Management Co. LLP 64,146,178 4.14%
Investor AB (Investment Company) 51,587,810 3.33%
The Vanguard Group, Inc. 48,125,000 3.11%
Capital Research & Management Co. (World Investors) 46,132,337 2.98%
Norges Bank Investment Management 30,921,000 2.00%
BlackRock Fund Advisors 27,770,415 1.79%
BlackRock Advisors (UK) Ltd. 21,488,979 1.39%
GQG Partners LLC 15,351,000 0.99%
SSgA Funds Management, Inc. 13,564,000 0.88%
Holdings
NameEquities%Valuation
ASTRAZENECA PHARMA INDIA LIMITED (506820) 18,750,000 75.0% 641,912,438 USD
DIZAL JIANGSU PHARMACEUTICAL CO. LTD. 108,923,023 29.8% 435,086,480 USD
ADC THERAPEUTICS SA (ADCT) 4,011,215 5.22% 31,889,159 USD
CIRCASSIA GROUP PLC (CIR) 71,059,999 16.9% 29,773,429 USD
INNATE PHARMA (IPH) 7,485,500 9.39% 20,065,107 USD
PIERIS PHARMACEUTICALS, INC. (PIRS) 3,584,230 4.97% 6,702,510 USD
ENTASIS THERAPEUTICS HOLDINGS, INC. 2,164,855 4.52% 4,762,681 USD
PHASEBIO PHARMACEUTICALS, INC. (PHAS) 3,004,554 6.17% 1,802,732 USD
ARIDIS PHARMACEUTICALS, INC. (ARDS) 884,956 5.00% 973,452 USD
Markets and indexes
- Main Market
- FTSE 100 / FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, Nasdaq 100, NASDAQ OMX Nordic 120, OMX Nordic 40, OMX Stockholm 30, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50
Stock Exchange Codes
- Bloomberg Code :  AZN:LN
- Reuters Code :  AZN.L
- Datastream Code :  
Company contact information
AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA Cambridge, Cambridgeshire

Phone : +44 (0)20 3749 5000
Fax : +44 (0)20 7604 8151
web site : https://www.astrazeneca.com/investor-relations.html
Brand Portfolio
In partnership withAllbrands.markets
More brands of AstraZeneca PLC
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
ASTRAZENECA PLC23.44%201 219
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
PFIZER, INC.-15.14%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131
NOVO NORDISK A/S4.76%240 550
MERCK & CO., INC.18.76%230 579
NOVARTIS AG-0.22%185 374
BRISTOL-MYERS SQUIBB COMPANY21.20%161 361
AMGEN INC.10.41%132 871
SANOFI-3.52%109 706
GSK PLC-11.78%71 163
BAYER AG15.21%54 546
DAIICHI SANKYO CO., LTD.25.71%52 755
CHUGAI PHARMACEUTICAL CO., LTD3.37%47 539
TAKEDA PHARMACEUTICAL COMPANY LIMITED21.07%43 952
JIANGSU HENGRUI MEDICINE CO., LTD.-26.17%35 420
ASTELLAS PHARMA INC.8.77%27 823
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-31.37%26 844
CATALENT, INC.-14.11%19 708